PL3858833T3 - Pochodna aminonorbornanu oraz sposób jej wytwarzania i zastosowanie - Google Patents

Pochodna aminonorbornanu oraz sposób jej wytwarzania i zastosowanie

Info

Publication number
PL3858833T3
PL3858833T3 PL19866403.9T PL19866403T PL3858833T3 PL 3858833 T3 PL3858833 T3 PL 3858833T3 PL 19866403 T PL19866403 T PL 19866403T PL 3858833 T3 PL3858833 T3 PL 3858833T3
Authority
PL
Poland
Prior art keywords
aminonorbornane
derivative
manufacture method
manufacture
aminonorbornane derivative
Prior art date
Application number
PL19866403.9T
Other languages
English (en)
Inventor
Rongyao CHEN
Original Assignee
Transthera Sciences (Nanjing), Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transthera Sciences (Nanjing), Inc. filed Critical Transthera Sciences (Nanjing), Inc.
Publication of PL3858833T3 publication Critical patent/PL3858833T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL19866403.9T 2018-09-29 2019-07-05 Pochodna aminonorbornanu oraz sposób jej wytwarzania i zastosowanie PL3858833T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811153123.3A CN110964016B (zh) 2018-09-29 2018-09-29 氨基降茨烷衍生物及其制备方法与应用
PCT/CN2019/094864 WO2020063012A1 (zh) 2018-09-29 2019-07-05 氨基降茨烷衍生物及其制备方法与应用

Publications (1)

Publication Number Publication Date
PL3858833T3 true PL3858833T3 (pl) 2026-04-20

Family

ID=69952831

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19866403.9T PL3858833T3 (pl) 2018-09-29 2019-07-05 Pochodna aminonorbornanu oraz sposób jej wytwarzania i zastosowanie

Country Status (12)

Country Link
US (2) US12291534B2 (pl)
EP (1) EP3858833B9 (pl)
JP (1) JP7370617B2 (pl)
KR (1) KR102760553B1 (pl)
CN (2) CN110964016B (pl)
AU (1) AU2019348752B2 (pl)
BR (1) BR112021005960A2 (pl)
DK (1) DK3858833T3 (pl)
ES (1) ES3056588T3 (pl)
MX (1) MX2021003662A (pl)
PL (1) PL3858833T3 (pl)
WO (1) WO2020063012A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021180107A1 (en) * 2020-03-12 2021-09-16 Fochon Pharmaceuticals, Ltd. Compounds useful as kinase inhibitors
CN114075190A (zh) 2020-08-20 2022-02-22 北京诺诚健华医药科技有限公司 杂环类btk抑制剂
CN114634512B (zh) * 2020-12-16 2023-11-14 江苏恒瑞医药股份有限公司 作为布鲁顿酪氨酸激酶抑制剂的化合物、其制备方法和医药应用
CN115417789B (zh) * 2022-09-03 2023-08-04 郑州大学 一种治疗帕金森氏病的化合物、其制备方法以及复方药物组合物和应用
TW202417448A (zh) 2022-10-26 2024-05-01 大陸商藥捷安康(南京)科技股份有限公司 咪唑并吡衍生物的晶型及其製備方法和用途
CN115947690B (zh) * 2022-12-13 2025-04-08 安徽医科大学 一种吲唑分子砌块的制备方法及其在药物合成中的应用
CN121926940A (zh) * 2024-10-28 2026-04-28 药捷安康(南京)科技股份有限公司 布鲁顿酪氨酸激酶抑制剂的用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2372694T3 (es) * 2003-10-15 2012-01-25 OSI Pharmaceuticals, LLC Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
EP2529621B1 (en) * 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
US8501724B1 (en) * 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
ME02990B (me) 2012-11-13 2018-10-20 Array Biopharma Inc Jedinjenja n-pirolidinil, n'-pirazolil- uree, tiouree, guanidina i cijanoguanidina kао inhibitori trka kinaze
RU2677884C2 (ru) 2013-09-30 2019-01-22 Гуанчжоу Иннокэа Фарма Тек Ко., Лтд. Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний
CN105764896A (zh) * 2013-09-30 2016-07-13 药品循环有限责任公司 布鲁顿氏酪氨酸激酶的抑制剂
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
CA2959602A1 (en) 2014-08-01 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2016106624A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine btk inhibitors
WO2016106623A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Benzamide imidazopyrazine btk inhibitors
US10611766B2 (en) * 2015-09-16 2020-04-07 Loxo Oncology Inc. Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
US10752639B2 (en) * 2016-03-16 2020-08-25 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-MLL and methods of use
CN107459521B (zh) * 2016-06-03 2021-04-16 合肥中科普瑞昇生物医药科技有限公司 Flt3激酶的新型抑制剂及其用途
CN106831789A (zh) * 2016-12-21 2017-06-13 南京亘泰医药技术有限公司 布鲁顿酪氨酸激酶抑制剂
CN107602564B (zh) * 2017-09-20 2019-08-30 南京亘泰医药技术有限公司 布鲁顿酪氨酸激酶抑制剂

Also Published As

Publication number Publication date
EP3858833A1 (en) 2021-08-04
WO2020063012A1 (zh) 2020-04-02
CN110964016A (zh) 2020-04-07
KR20210070304A (ko) 2021-06-14
EP3858833A4 (en) 2022-06-22
BR112021005960A2 (pt) 2021-07-13
CN112135826B (zh) 2021-05-28
CN112135826A (zh) 2020-12-25
US12291534B2 (en) 2025-05-06
CN110964016B (zh) 2021-05-28
EP3858833B9 (en) 2026-03-11
US20210332057A1 (en) 2021-10-28
EP3858833B1 (en) 2025-10-22
AU2019348752B2 (en) 2024-03-28
JP7370617B2 (ja) 2023-10-30
MX2021003662A (es) 2021-05-28
ES3056588T3 (en) 2026-02-23
CA3114259A1 (en) 2020-04-02
AU2019348752A1 (en) 2021-05-06
JP2022501403A (ja) 2022-01-06
US20220144843A1 (en) 2022-05-12
US11420975B2 (en) 2022-08-23
KR102760553B1 (ko) 2025-01-24
DK3858833T3 (da) 2025-12-22

Similar Documents

Publication Publication Date Title
ZA202001447B (en) M-diamide compound and preparation method therefor and use thereof
GB201805042D0 (en) Method and use
GB201805021D0 (en) Method and use
SG11202004253QA (en) Oil-and-fat composition and manufacturing method thereof
GB201905559D0 (en) Composition and method
GB201805024D0 (en) Method and use
GB201805103D0 (en) Method and use
SG11202003790PA (en) Composition and method
IL272924A (en) Methods for preparing and using endoxifen
PL4011898T3 (pl) Pochodna 3-hydroksy-5-pregnan-20-onu i jej zastosowanie
IL276053A (en) Therapeutic Gard and methods of its use
ZA202000850B (en) Herbicidal composition and method
GB201909542D0 (en) Composition and method
GB201700170D0 (en) Manufacturing method and apparatus
GB201805872D0 (en) Method and assembly
IL274784A (en) Triptolide derivative, method of preparation and its use
IL272858A (en) An assembly of ear plugs and a method for its creation
ZA201904187B (en) Method and composition
GB201817362D0 (en) Circuitry and method
GB201818904D0 (en) New formulations and methods
GB201811899D0 (en) Article and method
EP3661991A4 (en) CIS-POLYCYCLOOLEFINS AND PROCESSES FOR FORMING CIS-POLYCYCLOOLEFINS
GB201817688D0 (en) Circuitry and method
GB2580127B (en) Circuitry and method
GB2578574B (en) Circuitry and method